Bionano Genomics, Inc. (BNGO) vs Citius Pharmaceuticals, Inc. (CTXR)
A side-by-side comparison of Bionano Genomics, Inc. and Citius Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BNGO
Bionano Genomics, Inc.
$1.46HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
CTXR
Citius Pharmaceuticals, Inc.
$0.51HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — BNGO vs CTXR
growth of $100 · dividends reinvested · last 8yBNGO -100.0% (-62.5%/yr)CTXR -98.6% (-41.3%/yr)CTXR compounded faster over this window
Log scale — wide-divergence pair
BNGO CTXR
BNGO vs CTXR: by the numbers
- •BNGO is the larger company ($17M vs $14M market cap).
- •Both run net losses; BNGO's is the smaller (-106.58% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | BNGO | CTXR |
|---|---|---|
| P/S ratio | 0.55 | 1.96 |
| P/B ratio | 0.53 | 0.21 |
Profitability
| Metric | BNGO | CTXR |
|---|---|---|
| Gross margin | 21.95% | 0.00% |
| Operating margin | -116.95% | 0.00% |
| Net margin | -106.58% | -651.27% |
| ROE | -101.76% | -69.47% |
| ROIC | -85.72% | -67.62% |
Growth (annualized)
| Metric | BNGO | CTXR |
|---|---|---|
| Revenue CAGR (5Y) | 17.97% | N/A |
| Total return CAGR (5Y) | -78.37% | -60.04% |
Frequently asked
- How have BNGO and CTXR total returns compared?
- Over the past 5 years, BNGO delivered -78.37% and CTXR delivered -60.04% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bionano Genomics ROECitius Pharmaceuticals ROEBionano Genomics operating marginCitius Pharmaceuticals operating marginBionano Genomics revenue growthCitius Pharmaceuticals revenue growthBionano Genomics free cash flowCitius Pharmaceuticals free cash flow
Bionano Genomics & Citius Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.